|Bid||110.00 x 800|
|Ask||127.34 x 1300|
|Day's range||125.08 - 128.22|
|52-week range||96.66 - 181.07|
|Beta (5Y monthly)||0.50|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
REDWOOD CITY, Calif., September 15, 2021--Guardant Health, Inc. (Nasdaq: GH), along with leading academic institutions and pharmaceutical companies, share data highlighting molecular targets of importance, treatment resistance patterns, and advantages of using the Guardant360® liquid biopsy test to help improve the management of advanced solid cancers at the European Society for Medical Oncology (ESMO) 2021 virtual congress on September 16-21.
REDWOOD CITY, Calif., August 06, 2021--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the upcoming UBS Genomics 2.0 and MedTech Innovations Summit.
REDWOOD CITY, Calif., August 05, 2021--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, has announced a new leadership structure to support the Company’s strategic objectives for future growth. Under this structure, Helmy Eltoukhy, CEO, and AmirAli Talasaz, President, will serve as co-CEOs of Guardant Health. Both Eltoukhy and Talasaz will continue to serve on the Board of Directors and Eltoukhy will assume the role of Chairman. In addition, Meghan Joyce, Chief Operating